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The inhibitory receptor, Programmed Death 1 (PD-1), and its ligands (PD-L1/PD-L2) are thought to play a role in immune
surveillance during chronic viral infection. The contribution of the receptor/ligand pair during an acute infection is less
understood. To determine the role of PD-L1 and PD-L2 during acute ocular herpes simplex virus type 1 (HSV-1) infection, HSV-
1-infected mice administered neutralizing antibody to PD-L1 or PD-L2 were assessed for viral burden and host cellular immune
responses. Virus titers were elevated in cornea and trigeminal ganglia (TG) of anti-PD-L1-treated mice which corresponded
with a reduced number of CD80-expressing dendritic cells, PD-L1+ dendritic cells, and HSV-1-speciﬁc CD8+ T cells within the
draining (mandibular) lymph node (MLN). In contrast, anti-PD-L2 treatment had no eﬀect on viral replication or changes in the
MLN population. Notably, analysis of CD11c-enriched MLN cells from anti-PD-L1-treated mice revealed impaired functional
capabilities. These studies indicate PD-L1-expressing dendritic cells are important for antiviral defense during acute HSV-1
infection.
1.Introduction
The inﬂammatory response to microbial pathogens can have
detrimental consequences to the host especially at vulnerable
sites such as the eye. Fungal, bacterial, and viral infections
within the anterior segment of the eye can lead to signiﬁcant
inﬁltration of leukocytes as well as angiogenesis (both
lymph- and hemangiogenesis) in the cornea [1, 2]. Herpes
simplex virus type 1 (HSV-1) is a neurotropic member of the
alpha herpes virus family and a common human pathogen
that infects 60–90% of the adult worldwide population [3].
An HSV-1 infection can have devastating consequences to
vision as a result of a robust immune response to ep-
isodic reactivation of latent virus from reservoirs found in
the sensory ganglion (i.e., trigeminal ganglion [TG]) [4].
Reactivation begins with the resumption of the lytic viral
replication cycle in infected neurons. Infectious virions then
travel down trigeminal nerve ﬁbers to epithelial surfaces via
anterograde axonal transport. The trigeminal nerve provides
sensation to the lips, nose, and eye; therefore, each site is
susceptible to infection following reactivation.
Reactivation of latent HSV-1 results in repeated inﬂam-
mation and scarring in the stromal layer of the cornea which
can eventually progress to herpetic stromal keratitis (HSK)
[1, 5]. While there are a number of leukocyte subpopulations
that contribute to tissue pathology, CD4+ Th1 cells play a
key role with the production of interferon-γ (IFN-γ)[ 1, 5].
Consequently, control of the inﬂammatory nature of the
immune response to HSV-1 is a desirable outcome in order
to preserve the visual axis.
Thereareanumberofcandidatemoleculesandpathways
that have been shown to contribute to tissue pathology. One
such pathway is the PD-1:PD-L signaling pathway, a nega-
tiveregulatorypathwaythatresultsin T-cellexhaustion. Pro-
grammed Death 1 (PD-1) is a cell surface inhibitory receptor
found on activated T cells. Programmed Death Ligand 1
(PD-L1)isfoundonrestingTcells,Bcells,macrophages,and
dendritic cells, whereas expression of Programmed Death
Ligand 2 (PD-L2) is restricted to macrophages, dendritic
cells, and activated T cells [6–8]. T-cell exhaustion includes
a loss of IL-2 production and a decrease in proliferation
and killing capabilities [9]. PD-1:PD-L signaling also plays2 Clinical and Developmental Immunology
an important role in the maintenance of peripheral cell
tolerance and the generation of induced regulatory T cells
[10, 11]. PD-1:PD-L signaling also has been extensively
studied in the context of chronic viral infections such as
L C M V ,H I V ,a n dH C V[ 12–14]. During LCMV or HIV
infections, reduction in T-cell exhaustion via blockade of
PD-1:PD-L signaling signiﬁcantly reduces the viral load
[12, 13]. During chronic viral infection many factors can
contribute to T-cell exhaustion including the level of antigen
exposure, availability of CD4 T-cell help, and changes in
antigen presenting cell (APC) numbers [13]. Moreover,
changes in costimulatory molecule expression on the surface
of APCs can dramatically alter T-cell eﬀector function and
the course of viral infection [14].
Following ocular infection with HSV-1, PD-1 expression
is upregulated on CD4 T cells in both the cornea and drain-
ing lymph node [15]. Similarly, PD-L1 is up-regulated on
macrophages in both tissues [15]. Studies have also indicated
blocking PD-1:PD-L signaling during HSV-1 enhances
pathology by increasing the proliferation of HSV-speciﬁc
CD4 T cells that secrete IFN-γ [15]. Recent studies have
indicated a correlation between the levels of latent HSV-1
and the expression of PD-1 [16, 17]. However, no studies
have evaluated the impact of PD-1: PD-L signaling during
acute HSV-1 infection. To address this issue we compared
HSV-1-infected mice administered neutralizing antibody to
PD-L1 and PD-L2 in terms of viral replication in infected
tissues, the host cellular immune response phenotypically
and functionally within the cornea, TG, and draining lymph
node, and characterization of select intracellular signaling
molecules central to T-cell activation. Results from this study
indicate PD-L1 has a unique role during HSV-1 infection,
wherein blockade of PD-1:PD-L1 signaling decreases the
activation of dendritic cells resulting in an increased viral
load.
2.MaterialsandMethods
2.1. Virus and Mice. C57BL/6J mice were obtained from
The Jackson Laboratory and maintained at Dean McGee Eye
Institute. HSV glycoprotein-B- (gB-) speciﬁc T-cell receptor
transgenic mice were obtained from Dr. Francis Carbone
(University of Melbourne) and maintained at Dean McGee
Eye Institute. Animal treatment was consistent with the
National Institutes of Health Guidelines on the Care And
U s eo fL a b o r a t o r yA n i m a l s .A l lp r o c e d u r e sw e r ea p p r o v e d
by the University of Oklahoma Health Sciences Center and
Dean McGee Eye Institute Institutional Animal and Care Use
Committee. HSV-1 (strain McKrae) was grown and main-
tained as previously described [18].
2.2. HSV-1 Infection and Neutralizing Antibody Treatment.
Male and female C57BL/6 mice (6–10wk of age) were anes-
thetized by intraperitoneally (i.p.) injection with xylazine
(6.6mg/kg) and ketamine (100mg/kg) followed by scariﬁca-
tion of the cornea using a 25 5/8-guage needle. The tear ﬁlm
was then blotted, and the cornea was topically inoculated
with 1,000 plaque forming units (PFU) of HSV-1 in 3μL
of RPMI-1640 medium. At days 2, 4, and 6 after infection
(p.i.)micewereadministered200μgofneutralizingantibody
to PD-1, PD-L1, PD-L2, or isotype control (IgG) by i.p.
injection. Neutralizing antibodies and RatIgGwereobtained
from BioXcell. HSV-1 viral titers were determined in the
designated tissue at times p.i. by plaque assay as previously
described [19].
2.3. Flow Cytometry. At the indicated time p.i., mice were
exsanguinated and the cornea, draining (mandibular) lymph
node (MLN), and TG were removed, processed, labeled with
Abs, and analyzed using a Coulter Epics XL ﬂow cytometer
(Beckmancoulter)withtheabsolutenumberofcellsresiding
in the indicated tissue determined as previously described
[20]. The following Abs were used for the identiﬁcation
of cell populations; anti-CD3 (1742), anti-CD4 (RM4-5),
anti-CD8α (53-6.7), anti-NK1.1 (PK136), anti-CD45 (30-
F11), anti-F4/80 (MCA497FA), anti-GR1 (RB6-8C5), anti-
CD11c (HL3), anti-B220 (RA3-6B2). For tetramer staining,
cells were labeled with HSV peptide gB498−505 (SSIEFARL)-
speciﬁc major histocompatibility complex tetramer (MHC
Tetramer Lab, Baylor College of Medicine), anti-CD8, and
anti-CD45. Single cell suspensions of MLN and cornea
samples were also evaluated for Treg cells using a commercial
kit (eBiosciences).
2.4. Suspension Array. At the indicated time p.i., cornea, TG,
and MLN were removed from the exsanguinated mice and
assayed for the detection of CXCL1, CCL2, CCL5, and IFN-γ
using a suspension array system (Bio-Rad).
2.5. ELISA. At the indicated time p.i., the TG and cornea
were removed from the exsanguinated mice and placed in
500μL of 1X PBS containing a protease inhibitor mixture
(Calbiochem) on ice. Following homogenization with a tis-
sue miser (Fisher Scientiﬁc), the homogenates were clariﬁed
bycentrifugationat10,000×gfor1min.CXCL10levelswere
determined by ELISA according to the manufacturer’s in-
structions (Quantikine immunoassay; R and D Systems).
2.6. MLN T-Cell Cocultures. To assess MLN T-cell function
of HSV-1-infected mice treated with anti-PD-L1, anti-PD-
L2, or control IgG, CD11c+ cells were puriﬁed from the
spleen of untreated-C57BL/6 mice using MACS beads and
column (Miltenyi Biotec). One hundred thousand CD11c-
enriched cells were seeded into a 96-well round-bottom plate
and pulsed with UV-inactivated HSV-1 at a multiplicity of
infection (MOI) of 5 for 2hrs. Following incubation, the
media was removed from the CD11c-enriched cells and
single-cell suspensions of 1 × 106 MLN cells from HSV-
1 infected mice treated with anti-PD-L1, anti-PD-L2, or
control IgG were added. Cultures were incubated for 6 days
at 37◦C, 5% CO2, and 95% humidity. Following incubation,
the supernatants were removed and assayed for IL-2, IL-10,
andIFN-γ levelsbysuspensionarray(Bio-Rad).Background
levels of cytokine production were determined using non-
pulsedCD11c-enrichedcellscoculturedwithMLNcellsfrom
HSV-1-infected mice treated with anti-PD-L1, anti-PD-L2,
or control IgG. Background levels of cytokine productionClinical and Developmental Immunology 3
were subtracted from corresponding UV-inactivated HSV-1-
pulsed samples.
2.7. MLN CD11c Cell Coculture. To assess MLN CD11c+
cell function, CD11c+ cells were enriched from the MLN
of HSV-1-infected mice treated with anti-PD-L1, anti-PD-
L2, or control IgG using MACS beads and column (Miltenyi
Biotec). CD11c-enriched MLN cells (6.5 × 104 cells/well)
were seeded into a 96-well round-bottom plate and treated
with UV-inactivated HSV-1 at an MOI of 5 for 2hrs. Fol-
lowing incubation, the media was removed from the MLN
cells, and 1 × 106 spleen cells from HSV gB-speciﬁc T-cell
receptor transgenic mice were added. Cultures were incu-
bated for 3 days at 37◦C, 5% CO2, and 95% humidity.
Following incubation, the supernatants were removed and
assayed for IL-2, IL-10, and IFN-γ levels by suspension array
(Bio-Rad). Background levels of cytokine production were
determined using nonpulsed CD11c-enriched cells from
HSV-1-infected mice treated with anti-PD-L1, anti-PD-L2,
or control IgG, cocultured with MLN cells from uninfected
C57BL/6 mice. Background levels of cytokine production
were subtracted from corresponding UV-inactivated HSV-1
pulsed samples. Average background levels were 9.3pg/mL
for IL-2, 3274pg/mL for IL-10, and 347.8pg/mL for IFN-γ.
2.8. Statistics. The statistical module Prism was used to per-
form unpaired two-tailed Student’s t-test and analysis of
variance (ANOVA) with Tukey’s t-test. All error bars repre-
sent the standard errors of the means. A P value <0.05 was
considered signiﬁcant comparing isotypic control to anti-
PD-1-, anti-PD-L1-, or anti-PD-L2-treated mice.
3. Results
3.1. Anti-PD-L1 Antibody Treatment Increases HSV-1 Viral
Load. To assess the impact of PD-1:PD-L signaling during
HSV-1 infection, C57BL/6 mice were infected with HSV-
1 and then treated with anti-PD-L1, anti-PD-L2, anti-PD-
1, or isotypic control IgG. At 7 days p.i., cornea and TG
were removed and assayed for infectious virus by plaque
assay.Viraltitersweresigniﬁcantlyelevatedinthecorneaand
TG of anti-PD-L1 antibody-treated mice in comparison to
anti-PD-L2 or isotypic control-treated mice (Figure 1). By
comparison, there was no diﬀerence in the level of HSV-
1 recovered in the cornea and TG of anti-PD-1 antibody-
treated mice compared to control-treated or anti-PD-L2-
treated animals (Figure 1).
3.2. Impact of PD-L1 and PD-L2 Neutralizing Antibody
Treatment on MLN Leukocyte Subpopulations. To elucidate
the mechanism by which administering neutralizing PD-L1
antibodyincreasesHSV-1viraltiters,weinitiallyinvestigated
possiblechangesintheleukocytesubpopulationsoftheMLN
from HSV-1-infected, anti-PD-L1-, anti-PD-L2-, or control
IgG-treated mice using ﬂow cytometry. As expected but
never before reported, treatment of infected mice with PD-
L1 neutralizing antibody signiﬁcantly decreased the PD-L1-
expressingCD11c+ cellsintheMLN(Figure 2(b))andsignif-
icantly increased the number of PD-L2-expressing CD11c+
dendritic cells (Figure 2(c)). Animals treated with PD-L2
neutralizing antibody were found to possess significantly
fewer PD-L2-expressing CD11c+ dendritic cells (Figure 2(c))
in the MLN but with no signiﬁcant change in the number of
PD-L1-expressing dendritic cells (Figure 2(b)). Of interest,
there was a noted loss of CD11c+ cells expressing CD80+
in the mice treated with anti-PD-L1 but not anti-PD-L2
antibody or isotypic control (Figure 2(a)). However, there
was no diﬀerence in the number of CD11c+ dendritic cells
expressingCD80intheMLNofanti-PD-L2antibody-treated
mice in comparison to control-treated mice (Figure 2(a)).
Whereas CD86 is a costimulatory molecule that is also
expressed by activated dendritic cells, the number of MLN
CD11c+ cells that express CD86 in response to HSV-1 is low
and therefore, the measurement of CD86 expression was not
pursued.
Since there was a loss of the primary costimulatory mol-
ecules that drive clonal expansion of T cells, we next in-
vestigated the eﬀector immune cells associated with viral
surveillance. Treatment of HSV-1-infected mice with anti-
PD-L1 or anti-PD-L2 antibody did not modify expansion
of the CD4+ or CD8+ T-cell populations residing in the
MLN (data not shown). Moreover, there was no change in
the number of CD4+ Treg (CD3+CD4+Foxp3+) cells in the
MLN comparing control-treated to anti-PD-L1 and anti-
PD-L2 antibody-treated mice (Figure 3(a)). However, there
was a signiﬁcant reduction in the HSV-1 gB-speciﬁc (Tet+),
CD8+ T-cell population (Figures 3(b) and 3(c)). Anti-PD-
L2 antibody treatment also suppressed the number of HSV-
1 gB-speciﬁc (Tet+), CD8+ T-cell population but the loss
was not signiﬁcant (Figures 3(b) and 3(c)). It should also
be noted treatment of HSV-1 infected mice with anti-PD-L1
antibodysigniﬁcantlyincreasedthenumberofCD4+ PD1+ T
cells within the MLN but had no impact on PD1+ expression
on CD8+ T cells (Figures 3(d) and 3(e)).
3.3. Leukocyte Proﬁle of TG and Cornea Following Anti-PD-L1
or Anti-PD-L2 Treatment. Since anti-PD-L1 antibody-treat-
ed, HSV-1-infected mice displayed selective changes in
leukocyte subpopulations in the draining lymph node and
possessed signiﬁcantly more virus in the cornea and TG fol-
lowing ocular infection, we evaluated the leukocyte subpop-
ulations with the infected tissue as a means to associate
viral load with change in leukocyte inﬁltration. Analysis
of TG leukocyte subpopulations including NK cells (CD3−
NK1.1+), CD4 T cells (CD3+ CD4+), CD8 T cells (CD3+
CD8+), HSV-1 gB-speciﬁc CD8 T cells (Tet+ CD8+), plas-
macytoid dendritic cells (CD11c+ B220+), conventional den-
dritic cells (CD11c+ B220−), activated macrophages (F4/80+
Gr1+),andneutrophils(F4/80− Gr1+)revealednosigniﬁcant
diﬀerences (data not shown). Similar to the above results,
analysis of inﬁltrating CD4 T cells (CD3+ CD4+), CD8 T
cells (CD3+ CD8+), and HSV-1 gB-speciﬁc CD8 T cells (Tet+
CD8+) into the cornea showed no signiﬁcant diﬀerences
among the diﬀerent treatment groups (data not shown). The
number of CD4+ PD1+ T cells was also determined for the
cornea of HSV-1 infected mice and no signiﬁcant diﬀerences
were observed among the diﬀerent treatment groups (data
not shown).4 Clinical and Developmental Immunology
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Figure 1:HSV-1viralloadfollowinganti-PD-L1,anti-PD-L2,oranti-PD-1antibodytreatment.C57BL/6micewereinfectedwith1,000PFU
HSV-1/cornea. At days 2, 4, and 6 p.i. mice were administered neutralizing antibody to PD-L1, PD-L2, PD-1, or control IgG. The corneas
(a) and TG (b) were harvested at 7 days p.i. and HSV-1 viral titers were assessed by plaque assay. This ﬁgure summarizes three experiments
(n = 9). Each bar represents the mean ± SEM. ∗P<0.05 comparing the indicated group to the isotypic control antibody-treated group.
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Figure 2: MLN CD11c+ leukocyte subpopulations following HSV-1 infection and treatment with anti-PD-L1 or anti-PD-L2 antibody.
C57BL/6 mice were infected with 1,000 PFU HSV-1/cornea. At days 2, 4, and 6 p.i. mice were administered neutralizing antibody to PD-L1,
PD-L2, or control IgG. At day 7 p.i. mice were exsanguinated and the MLN was processed for ﬂow cytometry. (a) Total CD11c+ CD80+ cells.
(b) Total CD11c+ PD-L1+ cells. (c) Total CD11c+ PD-L2+ cells. This ﬁgure summarizes three experiments (n = 9). Each bar represents the
mean ± SEM. ∗P<0.05 comparing the indicated group to the isotypic control antibody-treated group.
3.4. Cytokine Levels of the TG and Cornea Following Anti-
PD-L1orAnti-PD-L2Treatment. Cytokinesandchemokines
at the site of infection dramatically impact both the innate
and adaptive immune response. Regarding ocular HSV-1
infection, IFN-γ, CCL2, CCL5, CXCL1, and CXCL10 have
been found to be expressed in the cornea and TG and are
thought to be instrumental in the clearance of the pathogen
directly or indirectly through the recruitment of eﬀector
immune cells [21]. Therefore, we investigated these analytes
in the cornea and TG as another means to explain diﬀerencesClinical and Developmental Immunology 5
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Figure 3: MLN T-cell subpopulations following HSV-1 infection and treatment with anti-PD-L1 or anti-PD-L2 antibody. C57BL/6 mice
were infected with 1,000 PFU HSV-1/cornea. At days 2, 4, and 6 p.i. mice were administered neutralizing antibody to PD-L1, PD-L2, or
control IgG. At day 7 p.i. mice were exsanguinated and the MLN was processed for ﬂow cytometry. (a) Total CD4+ CD25+ Foxp3+ cells. (b)
Total CD8+ Tet+ cells. (c) Representative ﬂow diagrams of lymph node stained for CD8 and expression of the TCR speciﬁc for the HSV-1
gB-derived epitope SSIEFARL, as indicated by staining with tetramer. (d) Total CD4+ PD-1+cells. (e) Total CD8+ PD-1+ cells. This ﬁgure
summarizes three experiments (n = 9). Each bar represents the mean ± SEM. ∗P<0.05 comparing the indicated group to the isotypic
control antibody-treated group.
in viral load between the anti-PD-L1 antibody-treated mice
to the control and anti-PD-L2 antibody-treated groups. Lev-
els of the antiviral cytokine IFN-γ were not found to
be diﬀerent in the TG comparing all groups of treated
animals (Figure 4(a)). In a similar display, the chemokines
CCL2, CCL5, and CXCL1 levels were also found to be
consistently expressed in the TG of the various treated
mouse groups (Figure 4(b)–4(d)). However, CXCL10 was
signiﬁcantly elevated in the TG of anti-PD-L1-treated mice
(Figure 4(e)). Comparison of IFN-γ, CCL2, CCL5, CXCL1,
and CXCL10 levels from the cornea of diﬀerent antibody
treatment groups revealed no diﬀerences (data not shown).
3.5. Functional Capabilities of MLN T Cells and Dendritic
Cells Following Blockade of PD-1:PD-L Signaling. Since the
inﬁltration of leukocytes into infected tissue may not reﬂect
the status of the cells in terms of antigen response, the
functional capabilities of T cells from HSV-1-infected mice6 Clinical and Developmental Immunology
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Figure 4: Cytokine expression following HSV-1 infection and treatment with anti-PD-L1 or anti-PD-L2 antibody. C57BL/6 mice were
infected with 1,000 PFU HSV-1/cornea. At days 2, 4, and 6 p.i. mice were administered neutralizing antibody to PD-L1, PD-L2, or control
IgG. At day 7 p.i. mice were exsanguinated and the TG was processed for suspension array or ELISA. (a) IFN-γ levels. (b) CXCL1 levels. (c)
CCL2 levels. (d) CCL5 levels. (e) CXCL10 levels. Cytokine levels are a summary of two to three experiments (n = 6–9). Each bar represents
the mean ± SEM expressed in pg/mg of tissue. ∗P<0.05 comparing the indicated group to the isotypic control antibody-treated group.
treated with anti-PD-L1, anti-PD-L2, or isotype control IgG
were assessed. Due to the low number of T cells residing in
the cornea and TG, it was not possible to accurately meas-
ure their status on a per animal basis. Consequently, MLN
were isolated from infected mice and processed into single-
cell suspension. Lymph node cells from isotypic control,
anti-PD-L1, or anti-PD-L2-antibody treated mice were
then cocultured with CD11c-enriched cells from untreated,
non-infected mouse spleens. The CD11c-enriched cells were
pulsed with UV-inactivated HSV-1 prior to culturing. Fol-
lowing 6 days of incubation, the supernatants from cultured
cells were collected and assayed for select cytokine content
by suspension array. The results show the MLN T cells
from antibody-treated groups of mice responded similarlyClinical and Developmental Immunology 7
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Figure 5: Functional analysis of MLN CD11c+ cells following HSV-1 infection and treatment with anti-PD-L1 or anti-PD-L2 antibody.
C57BL/6 mice were infected with 1,000 PFU HSV-1/cornea. At days 2, 4, and 6 p.i. mice were administered neutralizing antibody to PD-L1,
PD-L2, or control IgG. At day 7 p.i. the mice were exsanguinated and CD11c+ cells were highly enriched from the MLN. CD11c-enriched
MLNcellswere pulsedwithUV-inactivated HSV-1andcocultured with HSVgB-speciﬁcT-cell receptor Tcells oftransgenicmice. Following
incubation,thesupernatantswereremovedandassayedforIL-2(a),IL-10(b),andIFN-γ (c)levelsbysuspensionarray.Backgroundcytokine
levels were determined using nonpulsed CD11c+-enriched MLN cells. Background levels of cytokine production were subtracted from
corresponding UV-inactivated HSV-1-pulsed samples. This ﬁgure summarizes two experiments (n = 6). Each bar represents the mean ±
SEM. ∗P<0.05 comparing the indicated group to the isotypic control antibody-treated group.
to antigen-pulsed dendritic cells in the production of IL-
2, IL-10, and IFN-γ (data not shown). Since the data
suggested a deﬁciency was not found at the level of the T
cell, the eﬃciency of antigen presentation was investigated.
CD11c-enriched MLN cells from HSV-1 infected mice
treated with anti-PD-L1, anti-PD-L2, or isotype control IgG
were pulsed with UV-inactivated HSV-1 and cocultured with
spleen cells from naive HSV-1 gB-speciﬁc T-cell receptor
transgenic mice. Following 3 days of incubation, super-
natants were collected and assayed for cytokine content.
As seen in Figure 5(c), there was a signiﬁcant decrease in
IL-2 production by the HSV gB-speciﬁc T cells. Likewise,
the levels of IL-2 from the HSV gB-speciﬁc T cells were
also reduced when incubated with peptide-pulsed CD11c-
enriched dendritic cells from the anti-PD-L2 antibody-
treated mice but such levels did not reach signiﬁcance
(Figure 5(c)). In contrast, nearly equivalent levels of IL-10
and IFN-γ were found in the supernatants of HSV gB-
speciﬁc T cells stimulated with peptide pulsed dendritic cells
from all treatment groups of mice (Figures 5(a) and 5(b)).
It was somewhat surprising such a robust response was
found in the HSV gB-speciﬁc transgenic T cells relative to
IFN-γ and IL-10 production, two cytokines that typically
drive opposing TH responses.
4. Discussion
In this study, we report the administration of PD-L1 anti-
body during acute HSV-1 infection signiﬁcantly increases
viral load in the cornea and TG associated with a loss of
PD-L1-expressing dendritic cells and attenuated capacity to
present antigen by CD11c+ cells. During chronic LCMV
infection, treatment of mice with antibody that blocks
PD-1:PD-L1 signaling was found to improve the eﬀector
function of CD8+ T cells and decrease viral titers [22].
The therapeutic eﬀects of blocking the PD-1 pathway via
anti-PD-L1 antibody treatmentis further exempliﬁed during
HIV infections, wherein antibody treatment enhanced HIV-
speciﬁc CTL proliferation and cytokine production [23]. It is
likely the prevention of PD-1: PD-L1 interaction attenuates
T-cell exhaustion and facilitates CD8+ T-cell recovery as
demonstrated in chronic LCMV infection [24]. However,8 Clinical and Developmental Immunology
there are various levels by which PD-L1 expression may
inﬂuence the adaptive immune response.
An increase in Treg cells could impair eﬀector T cells
and, as a consequence, result in the augmentation in viral
load. However, anti-PD-L1 treatment during acute HSV-1
infection did not modify the number of Treg cells found
in the MLN. Nor did anti-PD-L1 antibody administration
alter the expansion of T-cell populations or NK cells residing
in the MLN. However, the costimulatory molecule, CD80,
was signiﬁcantly downregulated on CD11c+ cells from mice
treated with neutralizing PD-L1 antibody. The eﬀect was
speciﬁc since an equivalent dosage and treatment regimen
of anti-PD-L2 antibody had no such eﬀect on CD11c+ cells
within the MLN. The loss of CD80 expression correlated
with a signiﬁcant reduction in the number of HSV-1 gB-
speciﬁc CD8+ T cells within the MLN. A recent study
has indicated that depletion of dendritic cells or blockade
of CD80/86 signaling results in decreased virus-speciﬁc
CD8+ T cells and impaired viral clearance during inﬂuenza
infection [25]. It was also suggested that the absence of
CD28 signaling via CD80/CD86 could inhibit autocrine
IL-2 secretion by T cells. Furthermore, recombinant IL-2
treatment of CD80−/−CD86−/− mice restored the expansion
of eﬀector CD8 T cells [25]. The above results suggest neu-
tralizing PD-L1 may disrupt proper antigen presentation
through the down regulation of costimulatory molecules
such as CD80/CD86.
Whereas we found a reduction in the number of antigen-
speciﬁc cytotoxic T cells in the draining lymph node of anti-
PD-L1 antibody-treated mice, such a loss was not translated
within the infected tissue as similar numbers of HSV-1 gB-
speciﬁc CD8 T cells were recovered from the TG of all
HSV-1-infected, antibody-treated groups. Therefore, it was
hypothesized the function of the eﬀector cells rather than
absolute number of cells may be compromised and thus,
unable to eﬃciently monitor virus replication and spread.
Due to the low number of cells recovered from the infected
tissue, we investigated T cells obtained from the draining
lymphnodes,theMLN.SincePD-1expressionwasenhanced
on CD4+ T cells residing in the MLN of anti-PD-L1 anti-
body-treated mice, and PD-1 expression has previously been
associated with suppression of antiviral immunity [26], the
predicted inherent deﬁciency in eﬀector function appeared
to be a legitimate target of investigation. Using a system of in
vitrococulturing, we were able to assess MLN T-cell function
from infected, antibody-treated mice. The analysis revealed
T cells from HSV-1 infected, anti-PD-L1 or anti-PD-L2
antibody-treated mice were able to produce IL-2, IL-10, and
IFN-γ similar to T cells from the isotype antibody control-
treated mice. This result was in contrast to that observed
by Jun et al., wherein MLN T cells isolated from anti-PD-
L1 antibody-treated mice pulsed with UV-inactivated HSV-
1 produced twice as much IFN-γ as cells from the control
mice [15]. Diﬀerences between the previous study [15]a n d
current study include the use of HSV-resistant C57BL/6 mice
(for the current study) as compared to BALB/c, the strain
of virus (McKrae versus RE) used to infect mice, and the
course of anti-PD-L1 antibody treatment (days 2, 4 and 6
p.i. in the present study versus the day before and 2 days
p.i. in the previous study). Moreover, our study validated
the loss of PD-L1 expressing dendritic cells, whereas the
study by Jun et al. did not. In a reciprocal fashion, we found
CD11c-enriched cells from the MLN of anti-PD-L1 anti-
body-treated mice were deﬁcient in their ability to stimulate
HSV gB-speciﬁc CD8+ T-cell production of IL-2. Such an
observation is consistent with the reduction in clonal ex-
pansion of the antigen-speciﬁc CD8+ T cells in the MLN of
the anti-PD-L1 antibody-treated mice. However, the results
are not consistent with a global functional loss in antigen
presentation since copious amounts of IFN-γ and IL-10 were
produced by the HSV gB-speciﬁc T cells in response to
HSV-pulsed APCs. IL-2 levels have more recently been re-
ported to complement or enhance immune responses in-
cluding antiviral activity [27]. However, how changes in IL-
2 production may facilitate viral clearance in the presence
study is currently unclear.
Recent studies involving HSV-1 ocular infection and
PD-L1 have focused on herpetic stromal keratitis (HSK),
the expression of PD-L1, and the impact on latency [15–
17, 25, 26]. Initial studies revealed PD-1 expression was
upregulated on CD4+ T cells in the draining LN following
HSV-1 infection and furthermore, in vivo blockade of PD-
1:PD-L1 signaling enhanced HSK [15]. More recent studies
havefocusedonT-cellexhaustionandHSV-1latency.Studies
by Frank et al. revealed that CD4+ T-cell ablation during
acute HSV-1 infection alters the maintenance of HSV-1
latency and results in a population of HSV-1-speciﬁc CD8+
T cells which are functionally compromised [28]. This T-cell
populationalsoexhibitedincreasedlevelsofPD-1expression
[28]. However, blockade of PD-1:PD-L1 signaling following
CD4+ T-cell ablation restored the functional capabilities of
the HSV-1-speciﬁc CD8+ T cells [28]. Further studies inves-
tigating HSV-1 latency revealed a strong correlation between
the severity of eye disease, latency, and the expression of PD-
1 in the TG of infected mice [16, 17, 29]. More recently,
a direct role for HSV-1 LAT (latancy-associated transcript)
has been described wherein LAT expression upregulates PD-
L1 expression on neuronal- derived cells, further promot-
ing an environment for T-cell exhaustion [30]. Together,
these studies suggest PD-1:PD-L1 signaling mediates T-cell
exhaustionandlatencyduringHSV-1infection.However,no
study until now has investigated the impact of PD-1:PD-
L1 signaling during acute HSV-1 infection. Addition of this
data to the current knowledge base regarding PD-1:PD-L1
signaling and chronic viral infections further highlights the
multifaceted nature of this signaling pathway.
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